Bernstein analyst Rebecca Liang maintained a Hold rating on BeiGene (BGNE – Research Report) today and set a price target of $152.00. The company’s shares closed yesterday at $144.12.
According to TipRanks, Liang is an analyst with an average return of -28.8% and a 0.00% success rate.
Currently, the analyst consensus on BeiGene is a Strong Buy with an average price target of $251.39.
The company has a one-year high of $266.67 and a one-year low of $126.97. Currently, BeiGene has an average volume of 245K.
Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BGNE in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BeiGene (BGNE) Company Description:
BeiGene, Ltd.is a biopharmaceutical company. The company primarily focuses on developing molecularly targeted and immuno-oncology drugs for the treatment of cancer.
Read More on BGNE:
- BeiGene receives European Commission approval for tislelizumab
- Drugmakers look to alternative suppliers after draft U.S. legislation, FT says
- BeiGene price target lowered to $164.30 from $179.30 at BofA
- BeiGene price target lowered to $161 from $196 at Bernstein
- BeiGene Announces Executive Team Reshuffle and Director Pay Revision
